Clinical Effectiveness of Split-Virion Versus Subunit Trivalent Influenza Vaccines in Older Adults
Open Access
- 18 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (8) , 1170-1175
- https://doi.org/10.1093/cid/civ019
Abstract
Background. Inactivated influenza vaccines are manufactured using either split-virion or subunit methods. These 2 methods produce similar hemagglutinin antibody responses, but different cellular immune responses. Methods. We compared the effectiveness of split-virion influenza vaccines to that of subunit influenza vaccines using prospectively collected data from adults aged ≥50 years who sought care for acute respiratory illness during 3 influenza seasons: 2008–2009, 2010–2011, and 2011–2012 using a case-positive, control test–negative study design. Results. Complete data were available for 539 participants, of whom 68 (12.6%) had influenza detected. Influenza-infected patients were younger (P < .001), were more likely to have received no vaccine or the subunit influenza vaccine than the split-virion vaccine (P < .001), and more likely to have sought care in either the emergency department or the acute care clinic than the hospital (P = .001). Split-virion vaccine effectiveness was 77.8% (95% confidence interval [CI], 58.5%–90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, −11.8% to 70.9%), giving a difference in vaccine effectiveness of 33.5% (95% CI, 6.9%–86.7%). Conclusions. Studies need to be done to further explore if there are differences in clinical effectiveness in older adults for the 2 vaccine manufacturing methods.Keywords
This publication has 19 references indexed in Scilit:
- In the Shadow of Hemagglutinin: A Growing Interest in Influenza Viral Neuraminidase and Its Role as a Vaccine AntigenViruses, 2014
- Interim Estimates of 2013–14 Seasonal Influenza Vaccine Effectiveness — United States, February 20142014
- Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case–control study, influenza season 2012/13Eurosurveillance, 2014
- Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Adults, 2011–2012 Influenza SeasonClinical Infectious Diseases, 2013
- Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humansNature Medicine, 2012
- Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. CommunitiesPLOS ONE, 2011
- Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control StudyPLoS Medicine, 2011
- Effectiveness of Seasonal Vaccine in Preventing Confirmed Influenza-Associated Hospitalizations in Community Dwelling Older AdultsThe Journal of Infectious Diseases, 2011
- In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responsesVaccine, 2009
- Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split VaccinesClinical Drug Investigation, 1998